Antitumor activity of chLpMab-2, a human–mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity

Cancer Medicine

Volumn 6, Issue 4, 2017, Pages 768-777

  Kaneko, Mika K ^a   Yamada, Shinji ^a   Nakamura, Takuro ^a   Abe, Shinji ^b   Nishioka, Yasuhiko ^b   Kunita, Akiko ^c   Fukayama, Masashi ^c   Fujii, Yuki ^a   Ogasawara, Satoshi ^a,d   Kato, Yukinari ^a,e  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity; chimeric antibody; human podoplanin; monoclonal antibody

Indexed keywords

CHLPMAB 2 ANTIBODY; MONOCLONAL ANTIBODY; PODOPLANIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUNG CANCER; MESOTHELIOMA; MOUSE; NONHUMAN; OVARY CANCER; ANIMAL; CHO CELL LINE; CRICETULUS; DRUG SCREENING; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; HEK293 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016443794     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1049     Document Type: Article

References (54)

1. Martin-Villar, E., F. G. Scholl, C. Gamallo, M. M. Yurrita, M. Munoz-Guerra, J. Cruces, et al. 2005. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int. J. Cancer 113:899–910.
2. Yuan, P., S. Temam, A. El-Naggar, X. Zhou, D. Liu, J. Lee, et al. 2006. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107:563–569.
3. Takagi, S., T. Oh-hara, S. Sato, B. Gong, M. Takami, and N. Fujita. 2014. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Int. J. Cancer 134:2605–2614.
4. Kunita, A., T. G. Kashima, A. Ohazama, A. E. Grigoriadis, and M. Fukayama. 2011. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am. J. Pathol. 179:1041–1049.
5. Chandramohan, V., X. Bao, M. Kato Kaneko, Y. Kato, S. T. Keir, S. E. Szafranski, et al. 2013. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int. J. Cancer 132:2339–2348.
6. Kato, Y., M. K. Kaneko, A. Kuno, N. Uchiyama, K. Amano, Y. Chiba, et al. 2006. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 349:1301–1307.
7. Mishima, K., Y. Kato, M. K. Kaneko, Y. Nakazawa, A. Kunita, N. Fujita, et al. 2006. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. (Berl). 111:563–568.
8. Mishima, K., Y. Kato, M. K. Kaneko, R. Nishikawa, T. Hirose, and M. Matsutani. 2006. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. (Berl). 111:483–488.
9. Abe, S., Y. Morita, M. K. Kaneko, M. Hanibuchi, Y. Tsujimoto, H. Goto, et al. 2013. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J. Immunol. 190:6239–6249.
10. Kato, Y., G. Vaidyanathan, M. K. Kaneko, K. Mishima, N. Srivastava, V. Chandramohan, et al. 2010. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl. Med. Biol. 37:785–794.
11. Kato, Y., N. Fujita, A. Kunita, S. Sato, M. Kaneko, M. Osawa, et al. 2003. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J. Biol. Chem. 278:51599–51605.
12. Kato, Y., I. Sasagawa, M. Kaneko, M. Osawa, N. Fujita, and T. Tsuruo. 2004. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 23:8552–8556.
13. Kato, Y., M. Kaneko, M. Sata, N. Fujita, T. Tsuruo, and M. Osawa. 2005. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol. 26:195–200.
14. Kunita, A., T. G. Kashima, Y. Morishita, M. Fukayama, Y. Kato, T. Tsuruo, et al. 2007. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am. J. Pathol. 170:1337–1347.
15. Kaneko, M. K., Y. Kato, T. Kitano, and M. Osawa. 2006. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 378:52–57.
16. Pula, B., A. Jethon, A. Piotrowska, A. Gomulkiewicz, T. Owczarek, J. Calik, et al. 2011. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 59:1249–1260.
17. Kawase, A., G. Ishii, K. Nagai, T. Ito, T. Nagano, Y. Murata, et al. 2008. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int. J. Cancer 123:1053–1059.
18. Hoshino, A., G. Ishii, T. Ito, K. Aoyagi, Y. Ohtaki, K. Nagai, et al. 2011. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res. 71:4769–4779.
19. Schoppmann, S. F., B. Jesch, M. F. Riegler, F. Maroske, K. Schwameis, G. Jomrich, et al. 2013. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin. Exp. Metastasis 30:441–446.
20. Shindo, K., S. Aishima, K. Ohuchida, K. Fujiwara, M. Fujino, Y. Mizuuchi, et al. 2013. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol. Cancer. 12:168.
21. Inoue, H., H. Tsuchiya, Y. Miyazaki, K. Kikuchi, F. Ide, H. Sakashita, et al. 2014. Podoplanin expressing cancer-associated fibroblasts in oral cancer. Tumour Biol. 35:11345–11352.
22. Suzuki-Inoue, K., Y. Kato, O. Inoue, M. K. Kaneko, K. Mishima, Y. Yatomi, et al. 2007. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J. Biol. Chem. 282:25993–26001.
23. Kato, Y., M. K. Kaneko, A. Kunita, H. Ito, A. Kameyama, S. Ogasawara, et al. 2008. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 99:54–61.
24. Nagae, M., K. Morita-Matsumoto, M. Kato, M. K. Kaneko, Y. Kato, and Y. Yamaguchi. 2014. A Platform of C-Type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure. 22:1711–1721.
25. Wikstrand, C. J., L. P. Hale, S. K. Batra, M. L. Hill, P. A. Humphrey, S. N. Kurpad, et al. 1995. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:3140–3148.
26. Baselga, J., L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825–2831.
27. Goldstein, N. I., M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn. 1995. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1:1311–1318.
28. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, et al. 1994. Depletion of B-Cells in-Vivo by a Chimeric Mouse-Human Monoclonal-Antibody to Cd20. Blood 83:435–445.
29. Kato, Y., and M. K. Kaneko. 2014. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci. Rep. 4:5924.
30. Lohmueller, J. J., S. Sato, L. Popova, I. M. Chu, M. A. Tucker, R. Barberena, et al. 2016. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci. Rep. 6:31740.
31. Ogasawara, S., M. K. Kaneko, J. E. Price, and Y. Kato. 2008. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma. 27:259–267.
32. Takagi, S., S. Sato, T. Oh-hara, M. Takami, S. Koike, Y. Mishima, et al. 2013. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS ONE 8:e73609.
33. Nakazawa, Y., S. Takagi, S. Sato, T. Oh-hara, S. Koike, M. Takami, et al. 2011. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci. 102:2051–2057.
34. Marks, A., D. R. Sutherland, D. Bailey, J. Iglesias, J. Law, M. Lei, et al. 1999. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br. J. Cancer 80:569–578.
35. Kono, T., M. Shimoda, M. Takahashi, K. Matsumoto, T. Yoshimoto, M. Mizutani, et al. 2007. Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int. J. Oncol. 31:501–508.
36. Kaneko, M. K., A. Kunita, S. Abe, Y. Tsujimoto, M. Fukayama, K. Goto, et al. 2012. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci. 103:1913–1919.
37. Shiina, S., M. Ohno, F. Ohka, S. Kuramitsu, A. Yamamichi, A. Kato, et al. 2016. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. Cancer Immunol Res. 4:259–268.
38. Kaneko, M. K., H. Oki, Y. Hozumi, X. Liu, S. Ogasawara, M. Takagi, et al. 2015. Monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother. 34:310–317.
39. Kaneko, M. K., H. Oki, S. Ogasawara, M. Takagi, and Y. Kato. 2015. Anti-podoplanin monoclonal antibody LpMab-7 detects metastatic legions of osteosarcoma. Monoclon. Antib. Immunodiagn. Immunother. 34:154–161.
40. Kato, Y., A. Kunita, S. Abe, S. Ogasawara, Y. Fujii, H. Oki, et al. 2015. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget. 6:36003–36018.
41. Ogasawara, S., H. Oki, M. K. Kaneko, Y. Hozumi, X. Liu, R. Honma, et al. 2015. Development of monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother. 34:318–326.
42. Oki, H., M. K. Kaneko, S. Ogasawara, Y. Tsujimoto, X. Liu, M. Sugawara, et al. 2015. Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. Monoclon. Antib. Immunodiagn. Immunother. 34:174–180.
43. Oki, H., S. Ogasawara, M. K. Kaneko, M. Takagi, M. Yamauchi, and Y. Kato. 2015. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon. Antib. Immunodiagn Immunother. 34:44–50.
44. Kato, Y., S. Ogasawara, H. Oki, P. Goichberg, R. Honma, Y. Fujii, et al. 2016. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin. PLoS ONE 11:e0152912.
45. Kato, Y., S. Ogasawara, H. Oki, R. Honma, M. Takagi, Y. Fujii, et al. 2016. Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin. Monoclon. Antib. Immunodiagn. Immunother. 35:109–116.
46. Ogasawara, S., M. K. Kaneko, R. Honma, H. Oki, Y. Fujii, M. Takagi, et al. 2016. Establishment of Mouse Monoclonal Antibody LpMab-13 against Human Podoplanin. Monoclon Antib Immunodiagn Immunother 35:155–162.
47. Hayatsu, N., S. Ogasawara, M. K. Kaneko, Y. Kato, and H. Narimatsu. 2008. Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells. Biochem. Biophys. Res. Commun. 368:217–222.
48. Abe, S., M. K. Kaneko, Y. Tsuchihashi, T. Izumi, S. Ogasawara, N. Okada, et al. 2016. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. Cancer Sci. 107:1198–1205.
49. Kaneko, M. K., T. Nakamura, R. Honma, S. Ogasawara, Y. Fujii, S. Abe, et al. 2017. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med. 6:382–396.
50. Kaneko, M., Y. Kato, A. Kunita, N. Fujita, T. Tsuruo, and M. Osawa. 2004. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/podoplanin) molecules expressed in Chinese Hamster Ovary cells. J. Biol. Chem. 279:38838–38843.
51. Kaneko, M. K., Y. Kato, A. Kameyama, H. Ito, A. Kuno, J. Hirabayashi, et al. 2007. Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett. 581:331–336.
52. Kuno, A., Y. Kato, A. Matsuda, M. K. Kaneko, H. Ito, K. Amano, et al. 2009. Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification. Mol. Cell Proteomics 8:99–108.
53. Niwa, R., A. Natsume, A. Uehara, M. Wakitani, S. Iida, K. Uchida, et al. 2005. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306:151–160.
54. Gasdaska, J. R., S. Sherwood, J. T. Regan, and L. F. Dickey. 2012. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol. Immunol. 50:134–141.